GlassScriptPhysician profile
Denise Culpepper
NPI 1669782710
$4,561.99
in general payments reported to CMS, 2019-2025
31 companies · $618 in 2025
The $618 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,087 · 2022: $918 · 2023: $945 · 2024: $995 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $875.99 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $521.47 | 2021-2025 | Rexulti |
| Abbott Laboratories | $413.46 | 2021-2025 | Proclaim, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $324.41 | 2021-2025 | Trelegy Ellipta |
| Abbvie INC. | $321.80 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.88 | 2021-2025 | Jardiance |
| Mylan Specialty L.P. | $266.54 | 2021-2023 | Yupelri |
| Corcept Therapeutics | $233.98 | 2024 | Korlym |
| Novo Nordisk INC | $160.70 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $131.02 | 2021-2023 | Mounjaro |
| Radius Health, INC. | $127.35 | 2023-2025 | Tymlos |
| Amgen INC. | $115.08 | 2021-2025 | Evenity, Prolia |
| Genentech USA, INC. | $106.78 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.10 | 2023-2025 | Caplyta |
| Exact Sciences Corporation | $86.63 | 2023-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $75.94 | 2022-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $64.89 | 2022 | |
| Pfizer INC. | $54.93 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.38 | 2021-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $47.70 | 2021-2023 | |
| Astellas Pharma US INC | $27.80 | 2021 | |
| Depuy Synthes Sales INC. | $25.73 | 2023 | Monovisc |
| Genzyme Corporation | $23.61 | 2025 | |
| Itamar Medical INC | $19.78 | 2023 | Watchpatone |
| Biohaven Pharmaceuticals, INC. | $18.13 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.12 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.87 | 2021 | |
| Currax Pharmaceuticals LLC | $15.37 | 2023 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.86 | 2022 | |
| Axsome Therapeutics, INC. | $14.56 | 2024 | Auvelity |
| Idorsia Pharmaceuticals US INC | $14.13 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Culpepper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.